Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 10/20 | 0.53 |
| ▸ | CDK2 | P24941 | 6/20 | 0.53 |
| ▸ | SGK1 | O00141 | 1/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780577 | 1.00 | AKT1 (0.53) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4899252 | 1.00 | AKT1 (0.53) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4894737 | 0.94 | AKT1 (0.57) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4893264 | 0.94 | AKT1 (0.57) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4902382 | 0.93 | AKT1 (0.50) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4898308 | 0.93 | AKT1 (0.50) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4902138 | 0.92 | AKT1 (0.52) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4898250 | 0.92 | AKT1 (0.52) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4890399 | 0.92 | AKT1 (0.52) | AKT1CDK2SGK1CDC7CCNE1 | |
| SCHEMBL4898265 | 0.90 | AKT1 (0.56) | AKT1CDK2SGK1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | D SIDOCKY NEIL R | 2008-10-02 | — | — | US | disclosed |
| WO-2008036308-A2 | AMINO-SUBSTITUTED HETEROCYCLES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242694-A1 | Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, MTOR | AKT1 26/4885CDK2 64/4885SGK1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.